Development and current use of in hematopoietic stem cell transplantation in children and adolescents in Poland: Report of the Polish pediatric study group for hematopoietic stem cell transplantation of the Polish society for pediatric oncology and hematology. Issue 3 (June 2018)

• Record Type: Journal Article
• Authors: Wachowiak, Jacek; Chybicka, Alicja; Kowalczyk, Jerzy R.; Wysocki, Mariusz; Goździk, Jolanta; Gorczyńska, Ewa; Kałwak, Krzysztof; Styczyński, Jan; Drabko, Katarzyna; Pieczonka, Anna
• Is Part Of: Transfusion and apheresis science. Volume 57:Issue 3(2018)
• Page Start: 316
• Page End: 322
• Publication Date: 2018-06
• Subjects: Hematopoietic stem cell transplantation (HSCT) -- Hematopoietic stem cell source -- Hematopoietic stem cell donor -- Indications for HSCT -- Children -- Adolescents; Blood -- Transfusion -- Periodicals; Hemapheresis -- Periodicals; 615.39
• DOI: 10.1016/j.transci.2018.05.012
• Languages: English
• ISSNs: 1473-0502

Abstract

Abstract: The purpose of the survey was to evaluate the development and current use of hematopoietic stem cell transplantation (HSCT) in Poland between 1989–2016. The data for analysis (indication, number of performed HSCT, HSCT type, donor type, and stem cell source, year) have been collected annually using a standardized form. In Poland, between 1989–2016, the number of pediatric transplant beds grew from one to 40 and number and rate of transplants increased annually from 1/year (0.8/10 million) to 186/year (248/10 million). During the analyzed time period 2506 HSCTs were performed, including 1718 (68.6%) allogeneic transplants (allo-HSCT) with142 in 2016 and 788 (31.4%) autologous transplants (auto-HSCT) with 44 in 2016. Among 1718 allo-HSCT, 74% were performed for malignancy (ALL 47.2%, AML 26.2%, MDS 10.8%, CML 8.1%, NHL/HD 6.1%, others 2.5%), and 26% for non-malignant disorders (SAA 41%, congenital immunodeficiencies 35.4%, hereditary bone marrow failure 16%, metabolic disorders 7%). Among 788 auto-HSCTs, 30.8% were done for hematological malignancy (NHL 41.2%, AML 23.9%, HD 17.7%, ALL 15.6%, other 1.5%), while the remaining 69.2% for solid tumors (neuroblastoma 59.8%, Ewing's sarcoma 20.4%, other 19.8%). In Poland, between 1989–2016, the infrastructure indispensable to perform HSCT in every child with indication for this therapeutic procedure was created, and HSCT became an important part of pediatric treatment, especially in pediatric oncology, hematology, and in primary immunodeficiencies.